Sttr phase I: novel inhaled nitric oxide therapy for pulmonary treatments (COVID-19)

Ended Project Grant Awarded Last action

Award ID
2040043
Recipient
Awarding agency
Obligated
$256,000

Award facts

Assistance listing
47.041 Engineering
Completion date
Place of performance
Burlington, VT 05405, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The National Science Foundation awarded Medchem Partners LLC a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) for the period of August 1, 2021 through July 31, 2022. The grant funds the development of novel inhaled nitric oxide therapy for pulmonary treatments related to COVID-19. The Engineering program seeks to improve quality of life and economic strength through engineering research and innovation. This award supports Medchem Partners' work advancing new inhaled nitric oxide therapies, which have potential applications for treating lung conditions exacerbated by COVID-19.

Quick answers

Who received award 2040043?

2040043 was awarded to Medchem Partners LLC by Division of Industrial Innovation (National Science Foundation) on August 1, 2021.

How much is award 2040043 worth?

$256,000 has been obligated on 2040043.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login